LT3386509T - Kabergolino naudojimas gydant akių ligas, sukeltas padidėjusio kraujagyslių endotelio augimo faktoriaus lygio - Google Patents
Kabergolino naudojimas gydant akių ligas, sukeltas padidėjusio kraujagyslių endotelio augimo faktoriaus lygioInfo
- Publication number
- LT3386509T LT3386509T LTEP16831636.2T LT16831636T LT3386509T LT 3386509 T LT3386509 T LT 3386509T LT 16831636 T LT16831636 T LT 16831636T LT 3386509 T LT3386509 T LT 3386509T
- Authority
- LT
- Lithuania
- Prior art keywords
- cabergoline
- treatment
- growth factor
- vascular endothelial
- endothelial growth
- Prior art date
Links
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 title 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 title 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 title 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 title 1
- 229960004596 cabergoline Drugs 0.000 title 1
- 208000030533 eye disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL415170A PL232974B1 (pl) | 2015-12-09 | 2015-12-09 | Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń |
| PCT/IB2016/057483 WO2017098461A1 (en) | 2015-12-09 | 2016-12-09 | Use of agonists of type-2 dopaminergic receptors in treatment of conditions caused by elevated vascular endothelial growth factor levels |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3386509T true LT3386509T (lt) | 2020-01-27 |
Family
ID=57909808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP16831636.2T LT3386509T (lt) | 2015-12-09 | 2016-12-09 | Kabergolino naudojimas gydant akių ligas, sukeltas padidėjusio kraujagyslių endotelio augimo faktoriaus lygio |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20180360820A1 (lt) |
| EP (1) | EP3386509B1 (lt) |
| CN (1) | CN108472294B (lt) |
| CA (1) | CA3007953C (lt) |
| DK (1) | DK3386509T3 (lt) |
| ES (1) | ES2761875T3 (lt) |
| HR (1) | HRP20192256T1 (lt) |
| IL (1) | IL259903B (lt) |
| LT (1) | LT3386509T (lt) |
| PL (2) | PL232974B1 (lt) |
| PT (1) | PT3386509T (lt) |
| RU (1) | RU2698728C1 (lt) |
| WO (1) | WO2017098461A1 (lt) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL241086B1 (pl) * | 2017-09-26 | 2022-08-01 | Oseka Maciej | Pergolid do zastosowania w leczeniu zakrzepu naczyń siatkówki i/lub zatoru naczyń siatkówki oraz kompozycja farmaceutyczna zawierająca pergolid |
| PL430675A1 (pl) * | 2019-07-23 | 2021-01-25 | Osęka Maciej | Bromokryptyna do zastosowania w leczeniu chorób oczu związanych z podwyższonym poziomem śródbłonkowego czynnika wzrostu naczyń (VEGF) oraz kompozycja farmaceutyczna zawierająca bromokryptynę |
| CN113082031A (zh) * | 2021-03-09 | 2021-07-09 | 温州医科大学附属眼视光医院 | 一种多巴胺d1和d2受体非选择性激动剂在作为制备治疗眼部病理性血管新生药物的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4526892A (en) * | 1981-03-03 | 1985-07-02 | Farmitalia Carlo Erba, S.P.A. | Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas |
| CN1303286A (zh) * | 1998-03-27 | 2001-07-11 | 法玛西雅厄普约翰美国公司 | 卡麦角林在治疗多动腿综合征中的应用 |
| HUP0101803A3 (en) * | 1998-05-15 | 2002-10-28 | Upjohn Co | New use of cabergoline and pramipexole for preparation of medicaments |
| US20070155770A1 (en) * | 2006-01-03 | 2007-07-05 | Cedars-Sinai Medical Center | Treatment of anoragasmia or delayed orgasm |
| KR100923195B1 (ko) * | 2006-04-04 | 2009-10-22 | 고려대학교 산학협력단 | 도파민 ｄ2 수용체에 의한 도파민성 수용체 발달의 조절방법 및 이의 조성물 |
| EP2156833B1 (en) * | 2007-05-11 | 2011-11-30 | Santen Pharmaceutical Co., Ltd | Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient |
| CN102791134B (zh) * | 2009-12-04 | 2015-04-22 | 魄金莱默有限公司 | 用多巴胺再摄取抑制剂及类似物治疗糖尿病症状和延迟或预防糖尿病相关病理学病况的方法 |
-
2015
- 2015-12-09 PL PL415170A patent/PL232974B1/pl unknown
-
2016
- 2016-12-09 LT LTEP16831636.2T patent/LT3386509T/lt unknown
- 2016-12-09 WO PCT/IB2016/057483 patent/WO2017098461A1/en not_active Ceased
- 2016-12-09 US US16/060,517 patent/US20180360820A1/en not_active Abandoned
- 2016-12-09 DK DK16831636.2T patent/DK3386509T3/da active
- 2016-12-09 ES ES16831636T patent/ES2761875T3/es active Active
- 2016-12-09 RU RU2018124858A patent/RU2698728C1/ru active
- 2016-12-09 PL PL16831636T patent/PL3386509T3/pl unknown
- 2016-12-09 PT PT168316362T patent/PT3386509T/pt unknown
- 2016-12-09 HR HRP20192256TT patent/HRP20192256T1/hr unknown
- 2016-12-09 CA CA3007953A patent/CA3007953C/en active Active
- 2016-12-09 EP EP16831636.2A patent/EP3386509B1/en active Active
- 2016-12-09 CN CN201680072556.9A patent/CN108472294B/zh not_active Expired - Fee Related
-
2018
- 2018-06-07 IL IL259903A patent/IL259903B/en active IP Right Grant
-
2020
- 2020-03-31 US US16/836,168 patent/US11324740B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20200222387A1 (en) | 2020-07-16 |
| CN108472294B (zh) | 2021-07-13 |
| EP3386509A1 (en) | 2018-10-17 |
| ES2761875T3 (es) | 2020-05-21 |
| CN108472294A (zh) | 2018-08-31 |
| PL232974B1 (pl) | 2019-08-30 |
| PT3386509T (pt) | 2019-12-30 |
| PL415170A1 (pl) | 2017-06-19 |
| CA3007953C (en) | 2022-11-29 |
| DK3386509T3 (da) | 2019-12-16 |
| IL259903B (en) | 2020-09-30 |
| HRP20192256T1 (hr) | 2020-03-06 |
| WO2017098461A1 (en) | 2017-06-15 |
| IL259903A (en) | 2018-07-31 |
| CA3007953A1 (en) | 2017-06-15 |
| US20180360820A1 (en) | 2018-12-20 |
| RU2698728C1 (ru) | 2019-08-29 |
| EP3386509B1 (en) | 2019-09-18 |
| US11324740B2 (en) | 2022-05-10 |
| PL3386509T3 (pl) | 2020-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252159B (en) | Methods and formulations for the treatment of diseases of the blood vessels of the eye | |
| IL246791A0 (en) | Compositions and methods for treating eye diseases | |
| SMT201900176T1 (it) | Terapia con mrna per il trattamento di malattie oculari | |
| EP3137116A4 (en) | Dendrimer compositions and their use in treatment of diseases of the eye | |
| EP3030275A4 (en) | Method of treating peripheral artery diseases in lower limbs | |
| EP3030276A4 (en) | Method of treating peripheral artery diseases in lower limbs | |
| EP3060259A4 (en) | Methods of treating or preventing vascular diseases of the retina | |
| PL3277280T3 (pl) | Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych | |
| EP3030274A4 (en) | Method of treating peripheral artery diseases in lower limbs | |
| GB201417163D0 (en) | Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases | |
| PT3288588T (pt) | Agentes de reticulação melhorados de fibras de colagénio para uso no tratamento da ectasia corneana | |
| IL251769A0 (en) | Methods for treating eye conditions | |
| PL3292842T3 (pl) | Stent wewnątrznaczyniowy | |
| GB2541840B (en) | Ophthalmic composition for the treatment of ocular infection | |
| PL3049100T3 (pl) | Zmodyfikowane czynniki wzrostu fibroblastu-1 do leczenia zaburzeń ocznych | |
| IL248210A0 (en) | Methods and preparations for the treatment of blood vessel malformations | |
| GB201504387D0 (en) | Materials and methods for the treatment of vascular disease | |
| GB201503967D0 (en) | Biocompatible implants for use in tendon therapy | |
| IL246855A0 (en) | Materials for use in the treatment of retinitis | |
| IL246587A0 (en) | Preparations for use in the treatment of allergic conditions | |
| PL3386509T3 (pl) | Zastosowanie kabergoliny w leczeniu schorzeń oczu wywołanych przez podwyższone poziomy śródbłonkopochodnego czynnika wzrostu naczyń | |
| PT3229780T (pt) | Composições oftálmicas para utilização no tratamento da síndrome de olhos secos | |
| PL3302463T3 (pl) | Zastosowanie 3 deoksyantocyjanidyn w leczeniu chorób oczu | |
| HK1248110A1 (en) | Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases | |
| HK1231747A1 (en) | Dendrimer compositions and their use in treatment of diseases of the eye |